NASDAQ: GYREGyre Therapeutics Inc Stock
$17.11+0.78 (+4.78%)
Updated Apr 26, 2024
GYRE Price
$17.11
Fair Value Price
-$12.96
Market Cap
$1.46B
52 Week Low
$3.00
52 Week High
$30.40
P/E
-12.13x
P/B
-92.34x
P/S
14.91x
PEG
N/A
Dividend Yield
N/A
Revenue
$113.45M
Earnings
-$92.93M
Gross Margin
95.9%
Operating Margin
-74.41%
Profit Margin
-81.9%
Debt to Equity
-2.41
Operating Cash Flow
$26M
Beta
1.15
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
GYRE Overview
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GYRE scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GYRE ($17.11) is overvalued by 232% relative to our estimate of its Fair Value price of -$12.96 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GYRE ($17.11) is not significantly undervalued (232%) relative to our estimate of its Fair Value price of -$12.96 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GYRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more GYRE due diligence checks available for Premium users.
Be the first to know about important GYRE news, forecast changes, insider trades & much more!
GYRE News
Valuation
GYRE fair value
Fair Value of GYRE stock based on Discounted Cash Flow (DCF)
Price
$17.11
Fair Value
-$12.96
Undervalued by
232.00%
GYRE ($17.11) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GYRE ($17.11) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GYRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GYRE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-12.13x
Industry
14.88x
Market
41.14x
GYRE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-92.34x
Industry
5.85x
GYRE's financial health
Profit margin
Revenue
$113.5M
Net Income
-$89.1M
Profit Margin
-78.6%
GYRE's Earnings (EBIT) of -$84.42M... subscribe to Premium to read more.
Interest Coverage Financials
GYRE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$116.5M
Liabilities
$38.1M
Debt to equity
-2.41
GYRE's short-term assets ($57.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GYRE's short-term assets ($57.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GYRE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GYRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$37.8M
Investing
-$25.0M
Financing
$15.2M
GYRE's operating cash flow ($25.89M)... subscribe to Premium to read more.
Debt Coverage Financials
GYRE vs Biotech Stocks
Gyre Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.